Consulting fees and other vendor payments do not appear to be directly influencing U.S. physicians to implant more Watchman devices. Researcher Alexander Kolomaya, MD, discussed his team's findings on this topic.
The mobile power units of certain HeartMate 3 and HeartMate II LVADs have been experiencing “sudden, unexpected performance issues” such as turning on, off or even restarting with no warning. These issues can potentially be fatal, according to an alert shared by the FDA.
Same-day discharge won't always be a great fit after cardiac ablation, of course, but it has been associated with considerable patient satisfaction as well as improved efficiency and substantial cost savings. The Heart Rhythm Society and American College of Cardiology have shared a new scientific statement on the subject.
Field Medical's FieldForce Ablation System. Image courtesy of Field Medical.
Field Medical, founded in 2022 by Steven Mickelsen, MD, is set to make a significant splash at the Heart Rhythm Society's annual meeting in San Diego. The company also just raised $40 million in financing.
Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways.
Two of the world's leading medtech companies have been collaborating to improve patient access to CGM technology. It now looks like Medtronic and Abbott could be close to gaining FDA clearance and moving forward to the next phase of their partnership.
The devices are being recalled and discontinued after the FDA shared a series of concerns. This is a Class I recall, meaning using this system could result in serious injuries or death.
The world is in the throes of an AFib pandemic, one that could potentially get worse in the years ahead due to population growth, economic hardships and rigid resource limitations. According to the Heart Rhythm Society, one way to effectively combat this issue is the development of more AFib Centers of Excellence.
Reviewing data from more than 6,000 patients, researchers found little evidence of the "obesity paradox" observed elsewhere. Underweight TAVR patients, however, may face some significant long-term risks.
